BCL2 and lymphoma: The BCL-2 F104L mutation has been observed in non-Hodgkin lymphoma29 suggesting the mutation is viable in lymphomas, however these patients were not treated with drug and to date neither the F104L or F104C mutations have been reported in patients receiving venetoclax therapy.